Cargando…
Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
The efficiency of telestroke programs in improving the rates of recombinant tissue plasminogen activator (rtPA) in stroke patients has been reported. Previous studies have reported favorable treatment outcomes with the use of telestroke programs to improve the use of rtPA, but functional outcomes ar...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144501/ https://www.ncbi.nlm.nih.gov/pubmed/30245570 http://dx.doi.org/10.1177/1179069518793412 |
_version_ | 1783356113455939584 |
---|---|
author | Gainey, Jordan Brecthtel, Leanne Blum, Brice Keels, Aaliyah Madeline, Lee Lowther, Ervin Nathaniel, Thomas |
author_facet | Gainey, Jordan Brecthtel, Leanne Blum, Brice Keels, Aaliyah Madeline, Lee Lowther, Ervin Nathaniel, Thomas |
author_sort | Gainey, Jordan |
collection | PubMed |
description | The efficiency of telestroke programs in improving the rates of recombinant tissue plasminogen activator (rtPA) in stroke patients has been reported. Previous studies have reported favorable treatment outcomes with the use of telestroke programs to improve the use of rtPA, but functional outcomes are not fully understood. This study investigated the effect of telestroke technology in the administration of rtPA and related functional outcomes associated with baseline clinical variables. Retrospective data of a telestroke registry were analyzed. Univariate analysis was used to compare demographic and clinical variables in the rtPA group and the no rtPA group and between the improved functional ambulation group and the no improvement group. A stepwise binary logistic regression identified factors associated with improved functional outcome in the total telestroke population and in the subset of the telestroke population who received rtPA. In adjusted analysis and elimination of any multicollinearity for patients who received rtPA in the telestroke setting, obesity (odds ratio [OR] = 2.138, 95% confidence interval [CI], 1.164-3.928, P < .05), higher systolic blood pressure at the time of presentation (OR = 1.015, 95% CI, 1.003-1.027, P < .05), and baseline high-density lipoprotein at the time of admission (OR = 1.032, 95% CI, 1.005-1.059, P < .05) were associated with improved functional outcomes. Increasing age (OR = 0.940, 95% CI, 0.916-0.965, P < .0001) and higher calculated National Institutes of Health Stroke Scale (OR = 0.903, 95% CI, 0.869-0.937) were associated with a poorer outcome in rtPA-treated patients. Telestroke technology improves functional outcomes at spoke stations where neurological expertise is unavailable. Further studies are necessary to determine how telestroke technology can be optimized, especially to improve contraindications and increase eligibility for thrombolysis therapy. |
format | Online Article Text |
id | pubmed-6144501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-61445012018-09-21 Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology Gainey, Jordan Brecthtel, Leanne Blum, Brice Keels, Aaliyah Madeline, Lee Lowther, Ervin Nathaniel, Thomas J Exp Neurosci Cerebrovascular Disease and Stroke The efficiency of telestroke programs in improving the rates of recombinant tissue plasminogen activator (rtPA) in stroke patients has been reported. Previous studies have reported favorable treatment outcomes with the use of telestroke programs to improve the use of rtPA, but functional outcomes are not fully understood. This study investigated the effect of telestroke technology in the administration of rtPA and related functional outcomes associated with baseline clinical variables. Retrospective data of a telestroke registry were analyzed. Univariate analysis was used to compare demographic and clinical variables in the rtPA group and the no rtPA group and between the improved functional ambulation group and the no improvement group. A stepwise binary logistic regression identified factors associated with improved functional outcome in the total telestroke population and in the subset of the telestroke population who received rtPA. In adjusted analysis and elimination of any multicollinearity for patients who received rtPA in the telestroke setting, obesity (odds ratio [OR] = 2.138, 95% confidence interval [CI], 1.164-3.928, P < .05), higher systolic blood pressure at the time of presentation (OR = 1.015, 95% CI, 1.003-1.027, P < .05), and baseline high-density lipoprotein at the time of admission (OR = 1.032, 95% CI, 1.005-1.059, P < .05) were associated with improved functional outcomes. Increasing age (OR = 0.940, 95% CI, 0.916-0.965, P < .0001) and higher calculated National Institutes of Health Stroke Scale (OR = 0.903, 95% CI, 0.869-0.937) were associated with a poorer outcome in rtPA-treated patients. Telestroke technology improves functional outcomes at spoke stations where neurological expertise is unavailable. Further studies are necessary to determine how telestroke technology can be optimized, especially to improve contraindications and increase eligibility for thrombolysis therapy. SAGE Publications 2018-09-18 /pmc/articles/PMC6144501/ /pubmed/30245570 http://dx.doi.org/10.1177/1179069518793412 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Cerebrovascular Disease and Stroke Gainey, Jordan Brecthtel, Leanne Blum, Brice Keels, Aaliyah Madeline, Lee Lowther, Ervin Nathaniel, Thomas Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology |
title | Functional Outcome Measures of Recombinant Tissue Plasminogen
Activator–Treated Stroke Patients in the Telestroke Technology |
title_full | Functional Outcome Measures of Recombinant Tissue Plasminogen
Activator–Treated Stroke Patients in the Telestroke Technology |
title_fullStr | Functional Outcome Measures of Recombinant Tissue Plasminogen
Activator–Treated Stroke Patients in the Telestroke Technology |
title_full_unstemmed | Functional Outcome Measures of Recombinant Tissue Plasminogen
Activator–Treated Stroke Patients in the Telestroke Technology |
title_short | Functional Outcome Measures of Recombinant Tissue Plasminogen
Activator–Treated Stroke Patients in the Telestroke Technology |
title_sort | functional outcome measures of recombinant tissue plasminogen
activator–treated stroke patients in the telestroke technology |
topic | Cerebrovascular Disease and Stroke |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144501/ https://www.ncbi.nlm.nih.gov/pubmed/30245570 http://dx.doi.org/10.1177/1179069518793412 |
work_keys_str_mv | AT gaineyjordan functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology AT brecthtelleanne functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology AT blumbrice functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology AT keelsaaliyah functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology AT madelinelee functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology AT lowtherervin functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology AT nathanielthomas functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology |